European Journal of Cancer
IF
7.28
Papers
36190
Papers 10000
1 page of 1,000 pages (10k results)
Newest
#1Felix KeilH-Index: 24
#2Maximilian HartlH-Index: 1
Last. Richard GreilH-Index: 69
view all 14 authors...
Abstract Purpose Induction chemotherapy (ICT) with cisplatin (P), 5-FU (F) and taxanes (T) is a therapeutical option in patients suffering from locally advanced or unresectable stage III or IV squamous cell carcinoma of the head and neck (SCCHN). The role of ICT is controversial, and toxicity and/or delay of radiotherapy (RT) may reduce the potential benefit of this treatment regimen. Here, we report the results of a randomised phase II trial comparing TPF with TP + cetuximab (C). Patients and m...
Source
#1Laura MezquitaH-Index: 17
Last. Benjamin BesseH-Index: 74
view all 37 authors...
Abstract Background dNLR at the baseline (B), defined by neutrophils/[leucocytes-neutrophils], correlates with immune-checkpoint inhibitor (ICI) outcomes in advanced non–small-cell lung cancer (aNSCLC). However, dNLR is dynamic under therapy and its longitudinal assessment may provide data predicting efficacy. We sought to examine the impact of dNLR dynamics on ICI efficacy and understand its biological significance. Patients and methods aNSCLC patients receiving ICI at 17 EU/US centres were inc...
Source
#1Ying Zhu (University of the Sciences)H-Index: 15
#2Jianbo Tian (University of the Sciences)H-Index: 15
Last. Xiaoping Miao (University of the Sciences)H-Index: 69
view all 17 authors...
Abstract Aim This study aimed to identify the functional genes and genetic variants associated with the prognosis of pancreatic ductal adenocarcinoma (PDAC) and reveal the mechanism underlying their prognostic roles. Methods First, we implement a two-stage exome-wide association study in a total of 1070 patients to identify the genetic variant correlated with PDAC prognosis. Then we performed fine mapping through bioinformatics analysis and dual-luciferase reporter assays to reveal the causal fu...
Source
#1Jakob M. Riedl (Medical University of Graz)H-Index: 8
#2Florian Posch (Medical University of Graz)H-Index: 20
Last. Armin Gerger (Medical University of Graz)H-Index: 44
view all 17 authors...
Abstract Background Gemcitabine/nab-paclitaxel (GN) and FOLFIRINOX are standard first-line treatment options for advanced pancreatic ductal adenocarcinoma (aPDAC), but currently no prospective randomised head-to-head comparison between these treatments has yet been performed. Methods We conducted a comparative propensity score (PS) analysis of overall (OS) and progression-free survival (PFS) in a tri-centre cohort of patients with aPDAC undergoing palliative first-line treatment with either GN o...
Source
#1Lisanne Mout (Erasmus University Medical Center)
#2Lisanne F. van Dessel (Erasmus University Medical Center)H-Index: 4
Last. Martijn P. Lolkema (Erasmus University Medical Center)H-Index: 7
view all 20 authors...
Abstract Background Circulating tumour cell (CTC)–derived organoids have the potential to provide a powerful tool for personalised cancer therapy but are restrained by low CTC numbers provided by blood samples. Here, we used diagnostic leukapheresis (DLA) to enrich CTCs from patients with metastatic prostate cancer (mPCa) and explored whether organoids provide a platform for ex vivo treatment modelling. Methods We prospectively screened 102 patients with mPCa and performed DLA in 40 patients wit...
Source
#2Rianne de Vries (UvA: University of Amsterdam)H-Index: 3
Last. Paul BaasH-Index: 65
view all 6 authors...
INTRODUCTION Recent clinical trials with immune checkpoint inhibitors (ICIs) have shown that a subgroup of patients with malignant pleural mesothelioma (MPM) could benefit from these agents. However, there are no accurate biomarkers to predict who will respond. The aim of this study was to assess the accuracy of exhaled breath analysis using electronic technology (eNose) for discriminating between responders to ICI and non-responders. METHODS This proof-of-concept prospective observational study...
Source
#1Karen A. GelmonH-Index: 90
#2P. A. Fasching (FAU: University of Erlangen-Nuremberg)H-Index: 57
view all 11 authors...
BACKGROUND In the phase III OlympiAD trial, olaparib significantly increased progression-free survival (PFS) compared with chemotherapy of physician's choice in patients with germline BRCA-mutated (gBRCAm), human epidermal growth factor 2 (HER2)-negative metastatic breast cancer (mBC). The phase IIIb LUCY trial assessed the clinical effectiveness of olaparib in similar patients, in a setting reflecting clinical practice. METHODS This open-label, single-arm trial of olaparib (300 mg, twice daily)...
Source
#1Sebastiano ButiH-Index: 23
#2Melissa BersanelliH-Index: 20
Last. Alessio Cortellini (University of L'Aquila)H-Index: 15
view all 61 authors...
BACKGROUND We previously demonstrated the cumulative poor prognostic role of concomitant medications on the clinical outcome of patients with advanced cancer treated with immune checkpoint inhibitors, creating and validating a drug-based prognostic score to be calculated before immunotherapy initiation in patients with advanced solid tumours. This 'drug score' was calculated assigning score 1 for each between proton-pump inhibitor and antibiotic administration until a month before cancer therapy...
Source
#1Annika Kurreck (Charité)H-Index: 2
#2Johanna Weckwerth (Charité)
Last. Marianne Sinn (UHH: University of Hamburg)
view all 11 authors...
BACKGROUND Pancreatic ductal adenocarcinoma (PDAC) represents one of the most fatal malignancies worldwide. It is suggested that survival in PDAC depends, among other things, on pattern of disease recurrence. PATIENTS AND METHODS We performed a pooled analysis of the adjuvant therapy studies CONKO-001, CONKO-005, and CONKO-006, including a total of 912 patients with regard to prognostic factors in patients with recurrent disease. Overall survival from disease recurrence (OS 2) and disease-free s...
Source
#1Claudia Pasqualini (Université Paris-Saclay)
#2Jonathan Rubino (Université Paris-Saclay)
Last. Birgit Geoerger (Université Paris-Saclay)H-Index: 35
view all 17 authors...
Abstract Purpose AcSe-ESMART is a European multicentre, proof-of-concept multiarm phase I/II platform trial in paediatric patients with relapsed/refractory cancer. Arm G assessed the activity and safety of nivolumab in combination with metronomic cyclophosphamide +/- irradiation. Experimental design Following a Phase II Simon two-stage design, nivolumab was administered intravenously at 3 mg/kg every 2 weeks of a 28-day cycle, oral cyclophosphamide at 25 mg/m2 twice a day, 1 week on/1 week off. ...
Source
12345678910
Top fields of study
Cancer
Pathology
Oncology
Immunology
Cancer research
Breast cancer
Medicine